Asset Details
Do you wish to reserve the book?
Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance
Do you wish to request the book?
Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance
2024
Overview
Hospitals can leverage their position between the ultimate buyers and sellers of drugs to retain a substantial share of insurer pharmaceutical expenditures.
In this study, we used 2020-2021 national Blue Cross Blue Shield claims data regarding patients in the United States who had drug-infusion visits for oncologic conditions, inflammatory conditions, or blood-cell deficiency disorders. Markups of the reimbursement prices were measured in terms of amounts paid by Blue Cross Blue Shield plans to hospitals and physician practices relative to the amounts paid by these providers to drug manufacturers. Acquisition-price reductions in hospital payments to drug manufacturers were measured in terms of discounts under the federal 340B Drug Pricing Program. We estimated the percentage of Blue Cross Blue Shield drug spending that was received by drug manufacturers and the percentage retained by provider organizations.
The study included 404,443 patients in the United States who had 4,727,189 drug-infusion visits. The median price markup (defined as the ratio of the reimbursement price to the acquisition price) for hospitals eligible for 340B discounts was 3.08 (interquartile range, 1.87 to 6.38). After adjustment for drug, patient, and geographic factors, price markups at hospitals eligible for 340B discounts were 6.59 times (95% confidence interval [CI], 6.02 to 7.16) as high as those in independent physician practices, and price markups at noneligible hospitals were 4.34 times (95% CI, 3.77 to 4.90) as high as those in physician practices. Hospitals eligible for 340B discounts retained 64.3% of insurer drug expenditures, whereas hospitals not eligible for 340B discounts retained 44.8% and independent physician practices retained 19.1%.
This study showed that hospitals imposed large price markups and retained a substantial share of total insurer spending on physician-administered drugs for patients with private insurance. The effects were especially large for hospitals eligible for discounts under the federal 340B Drug Pricing Program on acquisition costs paid to manufacturers. (Funded by Arnold Ventures and the National Institute for Health Care Management.).
Publisher
Massachusetts Medical Society
Subject
/ Blue Cross Blue Shield Insurance Plans - economics
/ Blue Cross Blue Shield Insurance Plans - statistics & numerical data
/ Devices
/ Drugs
/ Economics, Hospital - statistics & numerical data
/ Humans
/ Infusions, Parenteral - economics
/ Infusions, Parenteral - statistics & numerical data
/ Insurance Claim Review - economics
/ Insurance Claim Review - statistics & numerical data
/ Insurance, Health - economics
/ Medicaid
/ Medicare
/ Oncology
/ Patients
/ Pharmaceutical Preparations - administration & dosage
/ Pharmaceutical Preparations - economics
/ Pharmacy
/ Prices
/ Professional Practice - economics
/ Professional Practice - statistics & numerical data
/ R&D
/ Sales
